The FDA plans to ask a panel of experts to evaluate the accuracy of a study of Johnson & Johnson and Zeltia's Yondelis after the agency's staff found discrepancies in radiology readings. J&J unit Ortho Biotech is seeking to launch Yondelis as a combination treatment with another J&J cancer drug, Doxil, for women with recurring ovarian cancer.

Full Story:
Reuters, Google

Related Summaries